Ronjon Chakraverty

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution
    Ronjon Chakraverty
    Royal Free Hampstead National Health Service NHS Trust, London, United Kingdom
    Blood 116:3080-8. 2010
  2. doi request reprint Allogeneic transplantation for lymphoma
    Ronjon Chakraverty
    Department of Haematology, University College London, Pond St, London, NW3 2QG, United Kingdom
    J Clin Oncol 29:1855-63. 2011
  3. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
  4. doi request reprint Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley St, London WC1E 6BT United Kingdom
    J Clin Oncol 29:971-8. 2011
  5. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
  6. ncbi request reprint High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
  7. doi request reprint Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation
    Guillermo Orti
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 88:1312-8. 2009
  8. doi request reprint Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma
    Kirsty J Thomson
    Royal Free and UniversityCollege Medical School, Guys Hospital, London, United Kingdom
    J Clin Oncol 27:426-32. 2009
  9. doi request reprint Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Medical School, University College London, London, United Kingdom
    Clin Infect Dis 52:49-57. 2011
  10. ncbi request reprint Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
    Ronjon Chakraverty
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 99:1071-8. 2002

Collaborators

Detail Information

Publications24

  1. doi request reprint Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution
    Ronjon Chakraverty
    Royal Free Hampstead National Health Service NHS Trust, London, United Kingdom
    Blood 116:3080-8. 2010
    ..In conclusion, alemtuzumab dose reduction to 30 mg is safe in the context of reduced intensity conditioning and HLA-identical sibling transplantation. This trial was registered at http://www.ncrn.org.uk as UKCRN study 1415...
  2. doi request reprint Allogeneic transplantation for lymphoma
    Ronjon Chakraverty
    Department of Haematology, University College London, Pond St, London, NW3 2QG, United Kingdom
    J Clin Oncol 29:1855-63. 2011
    ....
  3. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
    ..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning...
  4. doi request reprint Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley St, London WC1E 6BT United Kingdom
    J Clin Oncol 29:971-8. 2011
    ..We aimed to assess the impact of donor lymphocyte infusions (DLIs) on relapse incidence when administered for mixed chimerism and their utility as salvage therapy when given for relapse...
  5. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
    ..Thus, reduced-intensity conditioning regimens are being explored...
  6. ncbi request reprint High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
    ..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
  7. doi request reprint Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation
    Guillermo Orti
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 88:1312-8. 2009
    ..The drawback of DLI is the risk of graft-versus-host disease (GVHD). In this phase I study, we examined the potential of highly extensive CD8 depletion of DLI as a means of improving its safety profile...
  8. doi request reprint Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma
    Kirsty J Thomson
    Royal Free and UniversityCollege Medical School, Guys Hospital, London, United Kingdom
    J Clin Oncol 27:426-32. 2009
    ....
  9. doi request reprint Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Medical School, University College London, London, United Kingdom
    Clin Infect Dis 52:49-57. 2011
    ..The logistics of producing virus-specific T cells has, however, limited the application of cellular therapies, particularly following the introduction of more-recent regulatory stipulations...
  10. ncbi request reprint Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
    Ronjon Chakraverty
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 99:1071-8. 2002
    ..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...
  11. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
    ..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
  12. doi request reprint Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation
    Ben Carpenter
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 90:564-70. 2010
    ..The pattern of EBV reactivation in patients receiving allogeneic HSCT, incorporating in vivo or in vitro alemtuzumab as the method of TCD, is not known...
  13. pmc Depletion of CD11c(+) cells in the CD11c.DTR model drives expansion of unique CD64(+) Ly6C(+) monocytes that are poised to release TNF-α
    Shivajanani Sivakumaran
    Institute for Immunity and Transplantation, University College London, London, UK
    Eur J Immunol 46:192-203. 2016
    ..This finding will require consideration in experiments using depletion strategies to test the role of CD11c(+) DCs in immunity. ..
  14. pmc Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation
    Barry Flutter
    Transplantation Immunology Group, Department of Haematology, University College London, London, UK
    J Clin Invest 120:3855-68. 2010
    ....
  15. pmc Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors
    Hugh D Goold
    Division of Cancer Studies, Department of Haematology, University College London, Royal Free Campus, London NW3 2PF, United Kingdom
    J Immunol 186:4565-72. 2011
    ....
  16. pmc CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor
    Sara Ghorashian
    Institute of Immunity and Transplantation, University College London, Royal Free Hospital, London NW3 2PF, United Kingdom Transplantation Immunology Group, Department of Haematology, Division of Cancer Studies, University College London, London NW3 2PF, United Kingdom and
    J Immunol 194:1080-9. 2015
    ..Thus MHC class I-restricted CD4(+) T cells may enhance the efficacy of therapeutic TCR-engineered CD8(+) T cells and can be readily generated with the same TCR. ..
  17. ncbi request reprint The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells
    Ronjon Chakraverty
    Transplantation Immunology Group, Department of Hematology, University College London, London, UK
    J Immunol 181:6820-8. 2008
    ..We conclude that per-cell deficits in the function of donor CD8 cells activated in MC may be overcome by transferring larger numbers of T cells without inducing GVHD...
  18. pmc Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin
    Clare L Bennett
    Transplantation Immunology Group, Department of Haematology, Division of Cancer Studies, University College London, London, United Kingdom
    Blood 117:7063-9. 2011
    ..These data demonstrate a novel regulatory role for epidermal LCs during the effector phase of an inflammatory immune response in the skin...
  19. doi request reprint Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination
    Constandina Pospori
    Department of Immunology, University College London, Royal Free Hospital, London, UK
    Blood 117:6813-24. 2011
    ..This is the first demonstration that specificity for a tumor-associated self-antigen may drive differentiation of functionally competent memory T cells...
  20. doi request reprint CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status
    Rob S Sellar
    Department of Haematology, University College London Cancer Institute, London, United Kingdom Department of Haematology, University College London Hospital, London, United Kingdom and
    Blood 125:731-9. 2015
    ..Finally, conversion to donor chimerism after donor lymphocytes is associated with clinically occult transition to donor-derived immunity. ..
  21. doi request reprint Memory lapses in graft-versus-host disease
    Barry Flutter
    Transplantation Immunology Group, Department of Haematology, University College London, London, UK
    Eur J Immunol 41:2530-4. 2011
    ..In particular, the data suggest that it may be just as important to consider what naïve or effector cells have "lost" in their transition to memory...
  22. doi request reprint Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation
    Pedro Veliça
    Department of Haematology, Cancer Institute, University College London, London, United Kingdom Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Cancer Res 75:2641-52. 2015
    ..Unlike pharmacologic inhibitors, the genetic approach described here allows for upregulation as well as inhibition of the mTORC1 pathway and is highly selective for the therapeutic T cells without affecting systemic mTORC1 functions...
  23. doi request reprint A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
    Brian Philip
    UCL Cancer Institute, University College London, London, United Kingdom and
    Blood 124:1277-87. 2014
    ..We have tested the functionality of RQR8 in vitro and in vivo as well as in combination with T-cell engineering components. We predict that RQR8 will make T-cell gene therapy both safer and cheaper. ..
  24. pmc The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia
    Ronjon Chakraverty
    Department of Hematology, University College London, London, United Kingdom
    Blood 110:9-17. 2007
    ..Recent studies have suggested potential strategies by which the continued presence of host APCs can be exploited to prime strong donor immunity to tumors without the induction of GVHD...